par Louis, Renaud;Pilette, Charles;Michel, Olivier 
;Michils, Alain ;Brusselle, Guy;Poskin, Antoine;Van Schoor, Jan;Denhaerynck, Kris;Vancayzeele, Stefaan;Abraham, Ivo;Gurdain, Sandra
Référence Allergy, asthma, and clinical immunology, 15, page (20)
Publication Publié, 2019
;Michils, Alain ;Brusselle, Guy;Poskin, Antoine;Van Schoor, Jan;Denhaerynck, Kris;Vancayzeele, Stefaan;Abraham, Ivo;Gurdain, SandraRéférence Allergy, asthma, and clinical immunology, 15, page (20)
Publication Publié, 2019
Article révisé par les pairs
| Résumé : | Immunoglobulin E (IgE) is the treatment target of omalizumab, a monoclonal antibody indicated in the treatment of severe allergic asthma. Long-term variability of serum total IgE (sIgEtot) in asthmatics remains poorly documented. |
